Octozi Raises $3M Seed for AI in Clinical Trials

Octozi, a New York City-based artificial intelligence company, has secured 3 million dollars in seed funding. Surface Ventures led the investment round. What's interesting is Octozi automates clinical development workflows for pharmaceutical sponsors. The capital will expand its agentic AI platform and deepen integrations with clinical systems. Here's the thing: Clinical trials generate vast amounts of data, much of which is still processed manually. This adds time, cost, and risk to drug development. Octozi's platform integrates with existing systems, using a human-in-the-loop design to automate tasks like data cleaning and reporting. The technology combines large language models with deterministic clinical algorithms and medical knowledge. It already supports Phase III trials, which are large and complex. A study showed Octozi's AI increased data-cleaning throughput roughly six-fold and significantly reduced reviewer error rates. An economic analysis estimated potential savings of over 5 million dollars per study. The bottom line: This technology aims to improve data quality, ease pressure on clinical teams, and potentially speed up the delivery of life-saving therapies.